GSK717 is a selective agonist of the free fatty acid receptor 4 (FFA4, also known as GPR120). It is primarily utilized in the field of medical research, particularly in the study of metabolic disorders such as obesity and diabetes. By activating FFA4, it serves as a valuable tool for understanding the receptor's role in metabolic pathways, including regulation of metabolism, enhancement of insulin sensitivity, and anti-inflammatory effects. Researchers employ GSK717 in preclinical studies to investigate its potential therapeutic effects, evaluate efficacy and safety profiles, and develop novel treatments for metabolic syndromes. Its applications also extend to pharmacological experiments aimed at identifying new drug targets and optimizing therapeutic strategies for chronic metabolic conditions.